Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - flumetsulam - water dispersible granule - flumetsulam pyrimidine-sulfonamide active 800.0 g/kg - herbicide

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - dimethomorph - suspension concentrate - dimethomorph morpholine active 500.0 g/l - fungicide

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinochem international australia pty. ltd. - glufosinate-ammonium - soluble concentrate - glufosinate-ammonium organophosphorus-phosphinic ac active 200.0 g/l - herbicide

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - amisulbrom; copper (cu) present as tribasic copper sulphate - suspension concentrate - amisulbrom active 32.0 g/l; copper (cu) present as tribasic copper sulphate mineral-copper active 180.0 g/l - fungicide

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinochem international australia pty. ltd. - diuron - water dispersible granule - diuron urea-substituted active 900.0 g/kg - herbicide

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ceftolozane sulfate 1147mg equivalent to ceftolozane 1000 mg; tazobactam sodium 537mg equivalent to tazobactam 500 mg - powder for injection - 1000mg/500mg - active: ceftolozane sulfate 1147mg equivalent to ceftolozane 1000 mg tazobactam sodium 537mg equivalent to tazobactam 500 mg excipient: arginine citric acid sodium chloride - zerbaxa (ceftolozane/tazobactam) is indicated for the treatment of the following infections in adults and paediatric (birth to less than 18 years of age) patients with the following infections caused by designated susceptible microorganisms: - complicated intra-abdominal infections in combination with metronidazole. - complicated urinary tract infections, including pyelonephritis. consideration should be given to published therapeutic guidelines on the appropriate use of antibacterial agents.

Uusi-Seelanti - englanti - Ministry for Primary Industries

bayer new zealand limited - glyphosate - soluble concentrate - glyphosate 570 g/litre - herbicide - herbicide

Australia - englanti - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; water for injections - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use only in persons aged 5 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Kanada - englanti - Health Canada

vetoquinol n a inc - potassium peroxymonosulfate - powder for solution - 21.4% - potassium peroxymonosulfate 21.4% - disinfectants (for agents used on object)

Yhdysvallat - englanti - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - armodafinil (unii: v63xwa605i) (armodafinil - unii:v63xwa605i) - armodafinil 250 mg - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd). in osa, nuvigil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. if continuous positive airway pressure (cpap) is the treatment of choice for a patient, a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating nuvigil for excessive sleepiness. if nuvigil is used adjunctively with cpap, the encouragement of and periodic assessment of cpap compliance is necessary. in all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. the effectiveness of nuvigil in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials.